By Erin McElderry, Associate, Prevention, NASTAD
New HIV Infections by Transmission Category, 1980 – 2010*
In many ways, HIV prevention among people who inject drugs (PWID) has been a success story. Rates of new infections among PWID have declined dramatically since the beginning of the epidemic, due in part to the success of syringe services programs (SSPs) in preventing new HIV infections. However, this work is far from done. In 2010, PWID represented 8% of new HIV infections. The U.S. has also seen rising rates of young people addicted to prescription opioids transitioning to injection drug use. Continue reading
By Oscar Mairena, Manager, Viral Hepatitis/Policy and Legislative Affairs
Panelists at the NASTAD and Harm Reduction Coalition Congressional Briefing.
Last year, the Viral Hepatitis Prevention Coordinator (VHPC) in Massachusetts, Dan Church, wrote a post about the increasing rate of acute hepatitis C (HCV) infection among young persons who inject drugs in Massachusetts and the health department’s efforts to prevent new infections, identify existing cases, educate individuals vulnerable to acquisition, and enhance surveillance and data collection to better address the epidemic. Since then, more health departments have reported this trend, especially among young persons who begin using prescription opioids and transition to injecting heroin. Earlier this week, NASTAD partnered with the Harm Reduction Coalition to host a Congressional Briefing, An Emerging Epidemic: The Public Health Response to Hepatitis C Infection among Young People who Use Drugs, to bring this issue to light, educate Congressional staff and reinforce the role of public health in addressing emerging health concerns. Continue reading
By Maria Courogen, Director of the Office of Infectious Disease, Washington State Department of Health
Maria Courogen, Washington State AIDS Director, speaking at the launch of the updated Viral Hepatitis Action Plan.
In my role in Washington State, I oversee the state health department’s work in the areas of HIV, sexually transmitted diseases (STDs), tuberculosis and viral hepatitis. In my role as a member of NASTAD’s Executive Committee and Chair-Elect, I work with state health department colleagues across the country, many of whom have a similar portfolio of work, to provide leadership in the country’s response to HIV and hepatitis. As such, On April 3, I participated in an event hosted by the U.S. Department of Health and Human Services (HHS) for the release of the next iteration of the Viral Hepatitis Action Plan.